Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Likhitsup A, Razumilava N, Parikh ND. Treatment for advanced hepatocellular carcinoma: current standard and the future. Clin Liver Dis. 2019;13(1):13.

Article  Google Scholar 

Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020;5(1):1–3.

PubMed  PubMed Central  Google Scholar 

Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, Kamel IR, Ghasebeh MA, Pawlik TM. Hepatocellular carcinoma: from diagnosis to treatment. Surg Oncol. 2016;25(2):74–85.

Article  PubMed  Google Scholar 

Shimizu Y, Mizuno S, Fujinami N, Suzuki T, Saito K, Konishi M, Takahashi S, Gotohda N, Tada T, Toyoda H, Kumada T. Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer Sci. 2020;111(2):334–42.

Article  CAS  PubMed  Google Scholar 

Nishida T, Kataoka H. Glypican 3-targeted therapy in hepatocellular carcinoma. Cancers. 2019;11(9):1339.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H. Meta-analysis and systematic review of prognostic significance of Glypican-3 in patients with hepatitis B-related hepatocellular carcinoma. Virusdisease. 2019;30(2):193–200.

Article  PubMed  PubMed Central  Google Scholar 

Li N, Wei L, Liu X, Bai H, Ye Y, Li D, Li N, Baxa U, Wang Q, Lv L, Chen Y. A frizzled-like cysteine-rich domain in glypican-3 mediates wnt binding and regulates hepatocellular carcinoma tumor growth in mice. Hepatology. 2019;70(4):1231–45.

Article  CAS  PubMed  Google Scholar 

Montalbano M, Georgiadis J, Masterson AL, McGuire JT, Prajapati J, Shirafkan A, Rastellini C, Cicalese L. Biology and function of glypican-3 as a candidate for early cancerous transformation of hepatocytes in hepatocellular carcinoma. Oncol Rep. 2017;37(3):1291–300.

Article  CAS  PubMed  Google Scholar 

Qi XH, Wu D, Cui HX, Ma N, Su J, Wang YT, Jiang YH. Silencing of the glypican-3 gene affects the biological behavior of human hepatocellular carcinoma cells. Mol Med Rep. 2014;10(6):3177–84.

Article  CAS  PubMed  Google Scholar 

Capurro M, Martin T, Shi W, Filmus J. Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling. J Cell Sci. 2014;127(7):1565–75.

CAS  PubMed  Google Scholar 

Reischer T, Laccone F, Kasprian GJ, Yerlikaya-Schatten G. Simpson–Golabi–Behmel-syndrome in dichorionic-diamniotic twin pregnancy. Clin Pract. 2021;11(1):75–80.

Article  PubMed  PubMed Central  Google Scholar 

Filmus J, Capurro M. The role of glypicans in Hedgehog signaling. Matrix Biol. 2014;1(35):248–52.

Article  Google Scholar 

Kolluri A, Ho M. The role of glypican-3 in regulating Wnt, YAP, and hedgehog in liver cancer. Front Oncol. 2019;2(9):708.

Article  Google Scholar 

Shih TC, Wang L, Wang HC, Wan YJ. Glypican-3: a molecular marker for the detection and treatment of hepatocellular carcinoma. Liver Res. 2020;4(4):168–72.

Article  PubMed  PubMed Central  Google Scholar 

Moek KL, Fehrmann RS, van der Vegt B, de Vries EG, de Groot DJ. Glypican 3 overexpression across a broad spectrum of tumor types discovered with functional genomic mRNA profiling of a large cancer database. Am J Pathol. 2018;188(9):1973–81.

Article  CAS  PubMed  Google Scholar 

Chen C, Huang X, Ying Z, Wu D, Yu Y, Wang X, Chen C. Can glypican-3 be a disease-specific biomarker? Clin Transl Med. 2017;6(1):1–6.

Article  Google Scholar 

Cartier F, Indersie E, Lesjean S, Charpentier J, Hooks KB, Ghousein A, Desplat A, Dugot-Senant N, Trézéguet V, Sagliocco F, Hagedorn M. New tumor suppressor microRNAs target glypican-3 in human liver cancer. Oncotarget. 2017;8(25):41211.

Article  PubMed  PubMed Central  Google Scholar 

Shimizu Y, Suzuki T, Yoshikawa T, Endo I, Nakatsura T. Next-generation cancer immunotherapy targeting glypican-3. Front Oncol. 2019;10(9):248.

Article  Google Scholar 

Kaur SP, Cummings BS. Role of glypicans in regulation of the tumor microenvironment and cancer progression. Biochem Pharmacol. 2019;1(168):108–18.

Article  Google Scholar 

Zhou F, Shang W, Yu X, Tian J. Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev. 2018;38(2):741–67.

Article  CAS  PubMed  Google Scholar 

Liu X, Gao F, Jiang L, Jia M, Ao L, Lu M, Gou L, Ho M, Jia S, Chen F, Gao W. 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma. J Transl Med. 2020;18(1):1–2.

Article  Google Scholar 

Casale J, Crane JS. Biochemistry, Glycosaminoglycans.

Ghiselli G. Drug-mediated regulation of glycosaminoglycan biosynthesis. Med Res Rev. 2017;37(5):1051–94.

Article  CAS  PubMed  Google Scholar 

Zhang L. Glycosaminoglycan (GAG) biosynthesis and GAG-binding proteins. Prog Mol Biol Transl Sci. 2010;1(93):1–7.

Google Scholar 

Kinoshita T. Glycosylphosphatidylinositol (GPI) anchors: biochemistry and cell biology: introduction to a thematic review series. J Lipid Res. 2016;57(1):4–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Müller G. Novel applications for glycosylphosphatidylinositol-anchored proteins in pharmaceutical and industrial biotechnology. Mol Membr Biol. 2011;28(3):187–205.

Article  PubMed  Google Scholar 

Kakugawa S, Langton PF, Zebisch M, Howell SA, Chang TH, Liu Y, Feizi T, Bineva G, O’Reilly N, Snijders AP, Jones EY. Notum deacylates Wnt proteins to suppress signalling activity. Nature. 2015;519(7542):187–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zittermann SI, Capurro MI, Shi W, Filmus J. Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int J Cancer. 2010;126(6):1291–301.

Article  CAS  PubMed  Google Scholar 

Saad A, Liet B, Joucla G, Santarelli X, Charpentier J, Claverol S, Grosset CF, Trézéguet V. Role of glycanation and convertase maturation of soluble glypican-3 in inhibiting proliferation of hepatocellular carcinoma cells. Biochemistry. 2018;57(7):1201–11.

Article  CAS  PubMed  Google Scholar 

Tian Z, Hou X, Liu W, Han Z, Wei L. Macrophages and hepatocellular carcinoma. Cell Biosci. 2019;9(1):1.

Article  Google Scholar 

Yeung OW, Lo CM, Ling CC, Qi X, Geng W, Li CX, Ng KT, Forbes SJ, Guan XY, Poon RT, Fan ST. Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma. J Hepatol. 2015;62(3):607–16.

Article  CAS  PubMed  Google Scholar 

Takai H, Ashihara M, Ishiguro T, Terashima H, Watanabe T, Kato A, Suzuki M. Involvement of glypican-3 in the recruitment of M2-polarized tumor-associated macrophages in hepatocellular carcinoma. Cancer Biol Ther. 2009;8(24):2329–38.

Article  CAS  PubMed  Google Scholar 

Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application. J Hematol Oncol. 2017;10(1):1–2.

Article  Google Scholar 

Parayath N, Padmakumar S, Nair SV, Menon D, Amiji MM. Strategies for targeting cancer immunotherapy through modulation of the tumor microenvironment. Regen Eng Transl Med. 2020;6(1):29–49.

Article  Google Scholar 

Yao G, Yin J, Wang Q, Dong R, Lu J. Glypican-3 enhances reprogramming of glucose metabolism in liver cancer cells. BioMed Res Int. 2019;2019.

Mossenta M, Busato D, Dal Bo M